Mapping brain metals to evaluate therapies for neurodegenerative disease

CNS Neuroscience and Therapeutics

Volumn 17, Issue 4, 2011, Pages 256-268

  Gh Popescu, Bogdan Florin ^a   Nichol, Helen ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Chelator; Copper; Iron; Metal; Neurodegeneration; Synchrotron; X ray fluorescence; Zinc

Indexed keywords

CHELATING AGENT; CLIOQUINOL; COPPER; DEFEROXAMINE; IRON; PENICILLAMINE; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; BRAIN MAPPING; CHELATION THERAPY; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; DEGENERATIVE DISEASE; FRIEDREICH ATAXIA; HUMAN; REVIEW; SPECTROSCOPY; WILSON DISEASE; X RAY FLUORESCENCE;

BRAIN; BRAIN MAPPING; CHELATING AGENTS; CHELATION THERAPY; HUMANS; METALS; NEURODEGENERATIVE DISEASES; SPECTROMETRY, X-RAY EMISSION; SYNCHROTRONS; TREATMENT OUTCOME;

EID: 79952509014     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00149.x     Document Type: Review

References (147)

1. Bartzokis G, Tishler TA, Lu PH, et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging 2007;28:414-423.
2. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004;5:863-873.
3. Becker JS, Zoriy MV, Pickhardt C, Palomero-Gallagher N, Zilles K. Imaging of copper, zinc, and other elements in thin section of human brain samples (hippocampus) by laser ablation inductively coupled plasma mass spectrometry. Anal Chem 2005;77:3208-3216.
4. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114(Pt 4):1953-1975.
5. Dexter DT, Jenner P, Schapira AH, Marsden CD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992;32(Suppl):S94-S100.
6. Dexter DT, Sian J, Jenner P, Marsden CD. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. Adv Neurol 1993;60:273-281.
7. Dexter DT, Wells FR, Agid F, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987;2:1219-1220.
8. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
9. Hock A, Demmel U, Schicha H, Kasperek K, Feinendegen LE. Trace element concentration in human brain. Activation analysis of cobalt, iron, rubidium, selenium, zinc, chromium, silver, cesium, antimony and scandium. Brain 1975;98:49-64.
10. Duflou H, Maenhaut W, De Reuck J. Regional distribution of potassium, calcium, and six trace elements in normal human brain. Neurochem Res 1989;14:1099-1112.
11. Rajan MT, Jagannatha Rao KS, Mamatha BM, et al. Quantification of trace elements in normal human brain by inductively coupled plasma atomic emission spectrometry. J Neurol S 1997;146:153-166.
12. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005;23:1-25.
13. Perls M. Nachweis von Eisenoxyd in gewissen Pigmenten. Virchows Arch Path Anat 1867;39:42-48.
14. Zaleski SS. Das Eisen der Organe bei Morbus maculosus Werlhoffi. Arch Experiment Patholol Pharmacol 1887;23:77-90.
15. Gomori G. Microtechnical demonstartion of iron: A criticism of its methods. Am J Pathol 1936;12:655-663.
16. Meguro R, Asano Y, Odagiri S, Li C, Iwatsuki H, Shoumura K. Nonheme-iron histochemistry for light and electron microscopy: A historical, theoretical and technical review. Arch Histol Cytol 2007;70:1-19.
17. Pilloni L, Lecca S, Van Eyken P, et al. Value of histochemical stains for copper in the diagnosis of Wilson's disease. Histopathology 1998;33:28-33.
18. Henwood A. Current applications of orcein in histochemistry. A brief review with some new observations concerning influence of dye batch variation and aging of dye solutions on staining. Biotech Histochem 2003;78:303-308.
19. Ferenci P, Steindl-Munda P, Vogel W, et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. Clin Gastroenterol Hepatol 2005;3:811-818.
20. Danscher G, Howell G, Perez-Clausell J, Hertel N. The dithizone, Timm's sulphide silver and the selenium methods demonstrate a chelatable pool of zinc in CNS. A proton activation (PIXE) analysis of carbon tetrachloride extracts from rat brains and spinal cords intravitally treated with dithizone. Histochemistry 1985;83:419-422.
21. Lopez-Garcia C, Varea E, Palop JJ, et al. Cytochemical techniques for zinc and heavy metals localization in nerve cells. Microsc Res Tech 2002;56:318-331.
22. Popescu BF, George MJ, Bergmann U, et al. Mapping metals in Parkinson's and normal brain using rapid-scanning x-ray fluorescence. Phys Med Biol 2009;54:651-663.
23. Popescu BF, Robinson CA, Rajput A, Rajput AH, Harder SL, Nichol H. Iron, copper, and zinc distribution of the cerebellum. Cerebellum 2009;8:74-79.
24. Popescu BF, Robinson CA, Chapman LD, Nichol H. Synchrotron X-ray fluorescence reveals abnormal metal distributions in brain and spinal cord in spinocerebellar ataxia: A case report. Cerebellum 2009.
25. Collingwood J, Dobson J. Mapping and characterization of iron compounds in Alzheimer's tissue. J Alzheimers Dis 2006;10:215-222.
26. Ishihara R, Ide-Ektessabi A, Ikeda K, et al. Investigation of cellular metallic elements in single neurons of human brain tissues. Neuroreport 2002;13:1817-1820.
27. Linkous DH, Flinn JM, Koh JY, et al. Evidence that the ZNT-3 protein controls the total amount of elemental zinc in synaptic vesicles. J Histochem Cytochem 2008;56:3-6.
28. Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. J Struct Biol 2006;155:30-37.
29. Yoshida S, Ektessabi A, Fujisawa S. XANES spectroscopy of a single neuron from a patient with Parkinson's disease. J Synchrotron Radiat 2001;8(Pt 2):998-1000.
30. McCrea RP, Harder SL, Martin M, Buist R, Nichol H. A comparison of rapid-scanning X-ray fluorescence mapping and magnetic resonance imaging to localize brain iron distribution. Eur J Radiol 2008;68(3 Suppl):S109-S113.
31. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 1992;31:327-335.
32. Morris CM, Candy JM, Oakley AE, Bloxham CA, Edwardson JA. Histochemical distribution of non-haem iron in the human brain. Acta Anat (Basel) 1992;144:235-257.
33. Goldberg WJ, Allen N. Determination of Cu, Mn, Fe, and Ca in six regions of normal human brain, by atomic absorption spectroscopy. Clin Chem 1981;27:562-564.
34. Warren PJ, Earl CJ, Thompson RH. The distribution of copper in human brain. Brain 1960;83:709-717.
35. Altman PL, Dittmer DS. Biology data book. Maryland: FASEB, 1973.
36. Harauz G, Ishiyama N, Hill CM, Bates IR, Libich DS, Fares C. Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. Micron 2004;35:503-542.
37. Iyengar GV, Koomer WE, Bown HJM. The elemental composition of human tissues and body fluids. New York: Verlag-Chemie, 1978.
38. Cuajungco MP, Lees GJ. Zinc metabolism in the brain: Relevance to human neurodegenerative disorders. Neurobiol Dis 1997;4:137-169.
39. Mocchegiani E, Bertoni-Freddari C, Marcellini F, Malavolta M. Brain, aging and neurodegeneration: Role of zinc ion availability. Prog Neurobiol 2005;75:367-390.
40. Winterbourn CC. Toxicity of iron and hydrogen peroxide: The Fenton reaction. Toxicol Lett 1995;82-83:969-974.
41. Halliwell B. Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs Aging 2001;18:685-716.
42. Frazzini V, Rockabrand E, Mocchegiani E, Sensi SL. Oxidative stress and brain aging: Is zinc the link? Biogerontology 2006;7:307-314.
43. Arosio P, Ingrassia R, Cavadini P. Ferritins: A family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 2009;1790:589-599.
44. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996;1275:161-203.
45. Bou-Abdallah F, Santambrogio P, Levi S, Arosio P, Chasteen ND. Unique iron binding and oxidation properties of human mitochondrial ferritin: A comparative analysis with Human H-chain ferritin. J Mol Biol 2005;347:543-554.
46. O'Neill HA, Gakh O, Park S, et al. Assembly of human frataxin is a mechanism for detoxifying redox-active iron. Biochemistry 2005;44:537-545.
47. O'Neill HA, Gakh O, Isaya G. Supramolecular assemblies of human frataxin are formed via subunit-subunit interactions mediated by a non-conserved amino-terminal region. J Mol Biol 2005;345:433-439.
48. Nichol H, Gakh O, O'Neill HA, Pickering IJ, Isaya G, George GN. Structure of frataxin iron cores: An X-ray absorption spectroscopic study. Biochemistry 2003;42:5971-5976.
49. Popescu BF, Pickering IJ, George GN, Nichol H. The chemical form of mitochondrial iron in Friedreich's ataxia. J Inorg Biochem 2007;101:957-966.
50. Cavadini P, O'Neill HA, Benada O, Isaya G. Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia. Hum Mol Genet 2002;11:217-227.
51. Shadel GS. Mitochondrial DNA, aconitase 'wraps' it up. Trends Biochem Sci 2005;30:294-296.
52. Campanella A, Rovelli E, Santambrogio P, Cozzi A, Taroni F, Levi S. Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: Hypothesis for a protective role in Friedreich ataxia. Hum Mol Genet 2009;18:1-11.
53. O'Halloran TV, Culotta VC. Metallochaperones, an intracellular shuttle service for metal ions. J Biol Chem 2000;275:25057-25060.
54. Madsen E, Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci 2007;30:317-337.
55. Molina-Holgado F, Hider RC, Gaeta A, Williams R, Francis P. Metals ions and neurodegeneration. Biometals 2007;20:639-654.
56. Ricchelli F, Fusi P, Tortora P, et al. Destabilization of non-pathological variants of ataxin-3 by metal ions results in aggregation/fibrillogenesis. Int J Biochem Cell Biol 2007;39:966-977.
57. Bush AI. Metals and neuroscience. Curr Opin Chem Biol 2000;4:184-191.
58. Zatta P, Frank A. Copper deficiency and neurological disorders in man and animals. Brain Res Rev 2007;54:19-33.
59. Ortiz E, Pasquini JM, Thompson K, et al. Effect of manipulation of iron storage, transport, or availability on myelin composition and brain iron content in three different animal models. J Neurosci Res 2004;77:681-689.
60. Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR. Oligodendrocytes and myelination: The role of iron. Glia 2009;57:467-478.
61. Tsang D, Tsang YS, Ho WK, Wong RN. Myelin basic protein is a zinc-binding protein in brain: Possible role in myelin compaction. Neurochem Res 1997;22:811-819.
62. Kursula P, Merilainen G, Lehto VP, Heape AM. The small myelin-associated glycoprotein is a zinc-binding protein. J Neurochem 1999;73:2110-2118.
63. Snyder AM, Connor JR. Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 2009;1790:606-614.
64. Beard JL, Connor JR. Iron status and neural functioning. Annu Rev Nutr 2003;23:41-58.
65. Bolognin S, Drago D, Messori L, Zatta P. Chelation therapy for neurodegenerative diseases. Med Res Rev 2009;29:547-570.
66. Hider RC. Potential protection from toxicity by oral iron chelators. Toxicol Lett 1995;82-83:961-967.
67. Singh S, Khodr H, Taylor MI, Hider RC. Therapeutic iron chelators and their potential side-effects. Biochem Soc Symp 1995;61:127-137.
68. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 1996;271:20291-20299.
69. Liu ZD, Lockwood M, Rose S, Theobald AE, Hider RC. Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase. Biochem Pharmacol 2001;61:285-290.
70. Tsubaki T, Honma Y, Hoshi M. Neurological syndrome associated with clioquinol. Lancet 1971;1:696-697.
71. Oakley GP, Jr. The neurotoxicity of the halogenated hydroxyquinolines. A commentary. Jama 1973;225:395-397.
72. Schaumburg H, Herskovitz S. Copper deficiency myeloneuropathy: A clue to clioquinol-induced subacute myelo-optic neuropathy Neurology 2008;71:622-623.
73. Marmolino D, Acquaviva F. Friedreich's ataxia: From the (GAA)(n) repeat mediated silencing to new promising molecules for therapy. Cerebellum 2009;8:245-259.
74. Koga M, Tsutsumi A, Shirabe T. The pathogenesis of olivary changes in clioquinol intoxication. Neuropathology 1997;17:290-294.
75. Torkildsen O, Brunborg LA, Myhr KM, Bo L. The cuprizone model for demyelination. Acta Neurologica Scandinavica 2008;188:72-76.
76. Kumar N, Gross JB, Jr., Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology 2004;63:33-39.
77. Kumar N, Ahlskog JE, Klein CJ, Port JD. Imaging features of copper deficiency myelopathy: A study of 25 cases. Neuroradiology 2006;48:78-83.
78. Nations SP, Boyer PJ, Love LA, et al. Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease. Neurology 2008;71:639-643.
79. Schleper B, Stuerenburg HJ. Copper deficiency-associated myelopathy in a 46-year-old woman. J Neurol 2001;248:705-706.
80. Atwood CS, Scarpa RC, Huang X, et al. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 2000;75:1219-1233.
81. Danielsson J, Pierattelli R, Banci L, Graslund A. High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide. FEBS J 2007;274:46-59.
82. Syme CD, Nadal RC, Rigby SE, Viles JH. Copper binding to the amyloid-beta (Abeta) peptide associated with Alzheimer's disease: Folding, coordination geometry, pH dependence, stoichiometry, and affinity of Abeta-(1-28): Insights from a range of complementary spectroscopic techniques. J Biol Chem 2004;279:18169-18177.
83. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-676.
84. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 2003;60:1685-1691.
85. White AR, Du T, Laughton KM, et al. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 2006;281:17670-17680.
86. Collingwood JF, Chong RK, Kasama T, et al. Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core material. J Alzheimers Dis 2008;14:235-245.
87. Collingwood JF, Mikhaylova A, Davidson M, et al. In situ characterization and mapping of iron compounds in Alzheimer's disease tissue. J Alzheimers Dis 2005;7:267-272.
88. Gossuin Y, Hautot D, Muller RN, et al. Looking for biogenic magnetite in brain ferritin using NMR relaxometry. NMR Biomed 2005;18:469-472.
89. House E, Collingwood J, Khan A, Korchazkina O, Berthon G, Exley C. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheimers Dis 2004;6:291-301.
90. Leskovjan AC, Lanzirotti A, Miller LM. Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease. NeuroImage 2009;47:1215-1220.
91. Rajendran R, Minqin R, Ynsa MD, et al. A novel approach to the identification and quantitative elemental analysis of amyloid deposits - Insights into the pathology of Alzheimer's disease. Biochem Biophys Res Commun 2009;382:91-95.
92. Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 1998;19:339-345.
93. Corrigan FM, Reynolds GP, Ward NI. Hippocampal tin, aluminum and zinc in Alzheimer's disease. Biometals 1993;6:149-154.
94. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: Possible relation to oxidative stress. J Neurol Sci 1996;143:137-142.
95. Plantin LO, Lying-Tunnel U, Kristensson K. Trace elements in the human central nervous system studied with neutron activation analysis. Biol Trace Elem Res 1987;13:69-75.
96. Samudralwar DL, Diprete CC, Ni BF, Ehmann WD, Markesbery WR. Elemental imbalances in the olfactory pathway in Alzheimer's disease. J Neurol Sci 1995;130:139-145.
97. Thompson CM, Markesbery WR, Ehmann WD, Mao YX, Vance DE. Regional brain trace-element studies in Alzheimer's disease. Neurotoxicology 1988;9:1-7.
98. Ward NI, Manson JA. Neutron activation analysis techniques for identifying elemental status in Alzheimer's disease. J Radioanalytical Nucl Chem 1987;113:515-526.
99. Crapper McLachlan DR, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991;337:1304-1308.
100. Wallis LI, Paley MN, Graham JM, et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 2008;28:1061-1067.
101. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995;45:1138-1143.
102. Griffiths PD, Crossman AR. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 1993;4:61-65.
103. Mann VM, Cooper JM, Daniel SE, et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994;36:876-881.
104. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988;74:199-205.
105. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991;56:978-982.
106. Zecca L, Stroppolo A, Gatti A, et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A 2004;101:9843-9848.
107. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 1995;65:717-724.
108. Griffiths PD, Dobson BR, Jones GR, Clarke DT. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 1999;122:667-673.
109. Zecca L, Shima T, Stroppolo A, et al. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 1996;73:407-415.
110. Jellinger K, Kienzl E, Rumpelmair G, et al. Iron-melanin complex in substantia nigra of parkinsonian brains: An x-ray microanalysis. J Neurochem 1992;59:1168-1171.
111. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study. Brain Res 1992;593:343-346.
112. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: A neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003;26:578-580.
113. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: Implications for Parkinson's disease. Faseb J 2003;17:500-502.
114. Ebadi M, Pfeiffer RF, Murrin LC, Shiraga H. Metallothionein and oxidation reactions in Parkinson's disease. Proc West Pharmacol Soc 1991;34:285-290.
115. Barcia C, Fernandez Barreiro A, Poza M, Herrero MT. Parkinson's disease and inflammatory changes. Neurotox Res 2003;5:411-418.
116. Ebadi M, Hiramatsu M, Burke WJ, Folks DG, El-Sayed MA. Metallothionein isoforms provide neuroprotection against 6-hydroxydopamine-generated hydroxyl radicals and superoxide anions. Proc West Pharmacol Soc 1998;41:155-158.
117. Lee JY, Kim JH, Palmiter RD, Koh JY. Zinc released from metallothionein-iii may contribute to hippocampal CA1 and thalamic neuronal death following acute brain injury. Exp Neurol 2003;184:337-347.
118. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 1991;56:1441-1444.
119. Ben-Shachar D, Zuk R, Gazawi H, Ljubuncic P. Dopamine toxicity involves mitochondrial complex I inhibition: Implications to dopamine-related neuropsychiatric disorders. Biochem Pharmacol 2004;67:1965-1974.
120. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease. Neuron 2003;37:899-909.
121. Lan J, Jiang DH. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 1997;104:469-481.
122. Youdim MB, Fridkin M, Zheng H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J Neural Transm 2004;111:1455-1471.
123. Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997;6:1771-1780.
124. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-1427.
125. Gakh O, Adamec J, Gacy AM, Twesten RD, Owen WG, Isaya G. Physical evidence that yeast frataxin is an iron storage protein. Biochemistry 2002;41:6798-6804.
126. Rouault TA, Tong WH. Iron-sulfur cluster biogenesis and human disease. Trends Genet 2008;24:398-407.
127. Sanchez-Casis G, Cote M, Barbeau A. Pathology of the heart in Friedreich's ataxia: Review of the literature and report of one case. Can J Neurol Sci 1976;3:349-354.
128. Lamarche JB, Cote M, Lemieux B. The cardiomyopathy of Friedreich's ataxia morphological observations in 3 cases. Can J Neurol Sci 1980;7:389-396.
129. Bradley JL, Blake JC, Chamberlain S, Thomas PK, Cooper JM, Schapira AH. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet 2000;9:275-282.
130. Boddaert N, Le Quan Sang KH, Rotig A, et al. Selective iron chelation in Friedreich ataxia: Biologic and clinical implications. Blood 2007;110:401-408.
131. Waldvogel D, van Gelderen P, Hallett M. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann Neurol 1999;46:123-125.
132. Sohn YS, Breuer W, Munnich A, Cabantchik ZI. Redistribution of accumulated cell iron: A modality of chelation with therapeutic implications. Blood 2008;111:1690-1699.
133. Bibudhendra S. Copper transport and its defect in Wilson disease: Characterization of the copper-binding domain of Wilson disease ATPase. J Inorg Biochem 2000;79:187-191.
134. Gitlin JD. Wilson disease. Gastroenterology 2003;125:1868-1877.
135. Tao TY, Gitlin JD. Hepatic copper metabolism: Insights from genetic disease. Hepatology 2003;37:1241-1247.
136. Mufti AR, Burstein E, Csomos RA, et al. XIAP Is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders. Mol Cell 2006;21:775-785.
137. Schilsky ML. Wilson disease: Genetic basis of copper toxicity and natural history. Semin Liver Dis 1996;16:83-95.
138. Strickland GT, Frommer D, Leu ML, Pollard R, Sherlock S, Cumings JN. Wilson's disease in the United Kingdom and Taiwan. I. General characteristics of 142 cases and prognosis. II. A genetic analysis of 88 cases. Q J Med 1973;42:619-638.
139. Das SK, Ray K. Wilson's disease: An update. Nat Clin Pract 2006;2:482-493.
140. Medici V, Rossaro L, Sturniolo GC. Wilson disease-A practical approach to diagnosis, treatment and follow-up. Dig Liver Dis 2007;39:601-609.
141. Gooneratne SR, Howell JM, Gawthorne JM. An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep. Br Nutr 1981;46:469-480.
142. Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998;132:264-278.
143. Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P. Oral zinc therapy for Wilson's disease. Ann Intern Med 1983;99:314-319.
144. Hider RC, Ma Y, Molina-Holgado F, Gaeta A, Roy S. Iron chelation as a potential therapy for neurodegenerative disease. Biochem Soc Trans 2008;36(Pt 6):1304-1308.
145. Zhang L, Lichtmannegger J, Summer KH, Webb S, Pickering IJ, George GN. Tracing copper-thiomolybdate complexes in a prospective treatment for Wilson's disease. Biochemistry 2009;48:891-897.
146. Drysdale J, Arosio P, Invernizzi R, et al. Mitochondrial ferritin: A new player in iron metabolism. Blood Cells Mol Dis 2002;29:376-383.
147. Levi S, Arosio P. Mitochondrial ferritin. Int J Biochem Cell Biol 2004;36:1887-1889.